Active Ingredient History
Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures. As a bile acid, deoxycholic acid emulsifies fat in the gut. Synthetically derived deoxycholic acid, when injected, stimulates a targeted breakdown of adipose cells by disrupting the cell membrane and causing adipocytolysis. This results in an inflammatory reaction and clearing of the adipose tissue remnants by macrophages. Deoxycholic acid's actions are reduced by albumin and tissue-associated proteins, therefore its effect is limited to protein-poor subcutaneous fat tissue. Protein-rich tissues like muscle and skin are unaffected by deoxycholic acid, contributing to its safety profile. Deoxycholic acid is a cytolytic agent. The physiologic effect of deoxycholic acid is by means of decreased cell membrane integrity. Deoxycholic acid inhibits miR-21 expression in primary rat hepatocytes in a dose-dependent manner, and increases miR-21 pro-apoptotic target programmed cell death 4 (PDCD4) and apoptosis. Deoxycholic acid decreases NF-κB activity, shown to represent an upstream mechanism leading to modulation of the miR-21/PDCD4 pathway. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Subcutaneous Fat (approved 2015)
Adiposity (Phase 4)
Body Contouring (Phase 4)
Body Fat Distribution (Phase 4)
Candidiasis (Phase 3)
Candidiasis, Invasive (Phase 2)
Drug Evaluation (Phase 3)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Fat Body (Phase 4)
Hamartoma (Phase 1/Phase 2)
Healthy Volunteers (Phase 3)
Infections (Phase 3)
Leiomyosarcoma (Phase 2)
Leishmaniasis (Phase 2)
Leishmaniasis, Cutaneous (Phase 1/Phase 2)
Leishmaniasis, Visceral (Phase 4)
Leukemia (Phase 3)
Lipoma (Phase 2)
Liposarcoma (Phase 2)
Lung Diseases (Phase 3)
Lymphoma (Phase 3)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neurofibroma (Phase 1)
Neurofibromatosis 1 (Phase 1)
Ovarian Neoplasms (Phase 1/Phase 2)
Pain, Postoperative (Phase 2)
Rhytidoplasty (Phase 4)
Safety (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue